 Bridgette Jones
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 23 | 2024 | 157 | 10.090 |
Why?
| | Histamine | 8 | 2024 | 13 | 3.220 |
Why?
| | Racism | 4 | 2022 | 8 | 3.040 |
Why?
| | Humans | 44 | 2024 | 6896 | 2.190 |
Why?
| | Health Status Disparities | 5 | 2023 | 19 | 1.570 |
Why?
| | Child | 21 | 2024 | 3364 | 1.370 |
Why?
| | Biomedical Research | 2 | 2022 | 27 | 1.370 |
Why?
| | Stress, Psychological | 2 | 2019 | 32 | 1.350 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 65 | 1.150 |
Why?
| | Hypersensitivity | 3 | 2020 | 56 | 1.120 |
Why?
| | Genetic Predisposition to Disease | 5 | 2016 | 231 | 1.120 |
Why?
| | Health Equity | 2 | 2024 | 3 | 1.060 |
Why?
| | Food Hypersensitivity | 2 | 2024 | 18 | 1.050 |
Why?
| | Anti-Asthmatic Agents | 2 | 2020 | 11 | 1.020 |
Why?
| | Precision Medicine | 2 | 2020 | 45 | 1.010 |
Why?
| | Biomarkers | 3 | 2024 | 136 | 0.990 |
Why?
| | Pediatrics | 3 | 2020 | 186 | 0.960 |
Why?
| | Female | 15 | 2024 | 3525 | 0.880 |
Why?
| | United States | 6 | 2024 | 669 | 0.870 |
Why?
| | Adult | 8 | 2024 | 1181 | 0.830 |
Why?
| | Young Adult | 8 | 2024 | 647 | 0.820 |
Why?
| | Organizational Culture | 1 | 2021 | 4 | 0.790 |
Why?
| | Intention | 1 | 2021 | 4 | 0.790 |
Why?
| | Physicians, Women | 1 | 2021 | 3 | 0.790 |
Why?
| | Workplace | 1 | 2021 | 7 | 0.790 |
Why?
| | Amine Oxidase (Copper-Containing) | 4 | 2015 | 6 | 0.780 |
Why?
| | Genetic Association Studies | 3 | 2016 | 53 | 0.770 |
Why?
| | Male | 13 | 2024 | 3337 | 0.770 |
Why?
| | Environmental Exposure | 2 | 2019 | 29 | 0.770 |
Why?
| | Receptors, Histamine | 3 | 2015 | 3 | 0.750 |
Why?
| | Adolescent | 11 | 2024 | 2197 | 0.730 |
Why?
| | Cultural Diversity | 1 | 2020 | 2 | 0.710 |
Why?
| | Stress, Physiological | 1 | 2019 | 7 | 0.700 |
Why?
| | Internship and Residency | 1 | 2020 | 39 | 0.680 |
Why?
| | RNA, Messenger | 3 | 2014 | 115 | 0.650 |
Why?
| | Anti-Allergic Agents | 2 | 2016 | 6 | 0.580 |
Why?
| | Child, Preschool | 7 | 2024 | 1569 | 0.570 |
Why?
| | Laser-Doppler Flowmetry | 4 | 2024 | 7 | 0.570 |
Why?
| | Iontophoresis | 4 | 2024 | 7 | 0.570 |
Why?
| | Skin | 2 | 2024 | 15 | 0.570 |
Why?
| | Genetic Research | 1 | 2016 | 5 | 0.560 |
Why?
| | Genetic Linkage | 1 | 2016 | 12 | 0.560 |
Why?
| | Mouth Mucosa | 2 | 2013 | 2 | 0.550 |
Why?
| | Guanfacine | 1 | 2016 | 1 | 0.540 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2016 | 1 | 0.540 |
Why?
| | Histamine N-Methyltransferase | 1 | 2015 | 1 | 0.530 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 18 | 0.530 |
Why?
| | Histamine Antagonists | 2 | 2016 | 8 | 0.470 |
Why?
| | Middle Aged | 4 | 2018 | 608 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2016 | 348 | 0.450 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2013 | 10 | 0.440 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 15 | 0.440 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 101 | 0.420 |
Why?
| | Health Services Accessibility | 2 | 2022 | 39 | 0.350 |
Why?
| | Microvessels | 1 | 2009 | 4 | 0.330 |
Why?
| | Genetic Variation | 3 | 2016 | 174 | 0.330 |
Why?
| | Patient Education as Topic | 1 | 2008 | 53 | 0.310 |
Why?
| | Infant | 3 | 2024 | 1446 | 0.310 |
Why?
| | Patient Compliance | 1 | 2008 | 55 | 0.310 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 336 | 0.270 |
Why?
| | Treatment Outcome | 2 | 2023 | 622 | 0.250 |
Why?
| | Gene Frequency | 2 | 2015 | 90 | 0.250 |
Why?
| | Haplotypes | 2 | 2015 | 91 | 0.240 |
Why?
| | Desensitization, Immunologic | 1 | 2024 | 20 | 0.240 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 45 | 0.240 |
Why?
| | Skin Pigmentation | 1 | 2024 | 2 | 0.240 |
Why?
| | Genotype | 3 | 2014 | 410 | 0.230 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 6 | 0.220 |
Why?
| | Dermatitis, Atopic | 1 | 2023 | 7 | 0.220 |
Why?
| | Medicine | 1 | 2023 | 10 | 0.220 |
Why?
| | Disease Management | 2 | 2021 | 34 | 0.220 |
Why?
| | Hospitalization | 2 | 2023 | 210 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2016 | 149 | 0.210 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 126 | 0.200 |
Why?
| | Cities | 1 | 2022 | 10 | 0.200 |
Why?
| | Eczema | 1 | 2022 | 1 | 0.200 |
Why?
| | Pregnancy Complications | 1 | 2021 | 7 | 0.190 |
Why?
| | Lactation | 1 | 2021 | 5 | 0.190 |
Why?
| | Homicide | 1 | 2021 | 2 | 0.190 |
Why?
| | Telemedicine | 1 | 2022 | 59 | 0.190 |
Why?
| | Prognosis | 2 | 2013 | 211 | 0.180 |
Why?
| | Administration, Inhalation | 2 | 2011 | 19 | 0.180 |
Why?
| | Minority Groups | 1 | 2020 | 17 | 0.180 |
Why?
| | Disease Susceptibility | 1 | 2019 | 11 | 0.180 |
Why?
| | Community-Based Participatory Research | 1 | 2018 | 6 | 0.160 |
Why?
| | Case-Control Studies | 2 | 2021 | 215 | 0.150 |
Why?
| | Georgia | 1 | 2017 | 3 | 0.150 |
Why?
| | Research Subjects | 1 | 2016 | 2 | 0.140 |
Why?
| | Midwestern United States | 1 | 2016 | 34 | 0.140 |
Why?
| | Urban Population | 1 | 2016 | 27 | 0.140 |
Why?
| | Impulsive Behavior | 1 | 2016 | 3 | 0.140 |
Why?
| | Hyperkinesis | 1 | 2016 | 2 | 0.140 |
Why?
| | Problem Behavior | 1 | 2016 | 7 | 0.130 |
Why?
| | Histamine H1 Antagonists, Non-Sedating | 1 | 2016 | 3 | 0.130 |
Why?
| | Cetirizine | 1 | 2016 | 4 | 0.130 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 130 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 40 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 20 | 0.130 |
Why?
| | Models, Biological | 1 | 2016 | 65 | 0.130 |
Why?
| | Aged | 1 | 2016 | 378 | 0.130 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 274 | 0.120 |
Why?
| | Signal Transduction | 1 | 2015 | 132 | 0.120 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2014 | 8 | 0.120 |
Why?
| | Sex Factors | 1 | 2014 | 68 | 0.120 |
Why?
| | Pilot Projects | 1 | 2014 | 120 | 0.120 |
Why?
| | Blood Flow Velocity | 2 | 2016 | 6 | 0.120 |
Why?
| | Immunoglobulin E | 1 | 2013 | 22 | 0.110 |
Why?
| | Skin Tests | 2 | 2013 | 19 | 0.110 |
Why?
| | Area Under Curve | 1 | 2013 | 35 | 0.110 |
Why?
| | Rhinitis, Allergic | 1 | 2013 | 10 | 0.110 |
Why?
| | Genes, Essential | 1 | 2013 | 2 | 0.110 |
Why?
| | RNA Stability | 1 | 2013 | 4 | 0.110 |
Why?
| | Genetic Markers | 1 | 2013 | 22 | 0.110 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 49 | 0.110 |
Why?
| | Gene Expression | 1 | 2013 | 67 | 0.110 |
Why?
| | Linear Models | 1 | 2013 | 56 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2013 | 58 | 0.110 |
Why?
| | Models, Genetic | 1 | 2013 | 33 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 99 | 0.110 |
Why?
| | Pharmacogenetics | 2 | 2011 | 176 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 84 | 0.110 |
Why?
| | Flushing | 1 | 2012 | 4 | 0.100 |
Why?
| | Exanthema | 1 | 2012 | 4 | 0.100 |
Why?
| | Pruritus | 1 | 2012 | 4 | 0.100 |
Why?
| | Erythema | 1 | 2012 | 5 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2013 | 199 | 0.100 |
Why?
| | Social Determinants of Health | 2 | 2022 | 13 | 0.100 |
Why?
| | Vancomycin | 1 | 2012 | 17 | 0.100 |
Why?
| | Animals | 2 | 2013 | 729 | 0.100 |
Why?
| | Research Design | 2 | 2023 | 63 | 0.100 |
Why?
| | Phenotype | 1 | 2013 | 257 | 0.100 |
Why?
| | Dideoxynucleosides | 1 | 2011 | 1 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2011 | 11 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2011 | 9 | 0.100 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 13 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 37 | 0.100 |
Why?
| | Meningeal Neoplasms | 1 | 1991 | 4 | 0.090 |
Why?
| | Prednisone | 1 | 1991 | 12 | 0.090 |
Why?
| | Risk Factors | 2 | 2012 | 487 | 0.090 |
Why?
| | Leukemia | 1 | 1991 | 15 | 0.090 |
Why?
| | Dexamethasone | 1 | 1991 | 29 | 0.090 |
Why?
| | Inflammation | 1 | 2010 | 51 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 90 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 66 | 0.090 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1991 | 52 | 0.090 |
Why?
| | Social Class | 1 | 2009 | 11 | 0.090 |
Why?
| | Child Development | 1 | 2009 | 44 | 0.080 |
Why?
| | Administration, Cutaneous | 1 | 2009 | 4 | 0.080 |
Why?
| | Needs Assessment | 1 | 2008 | 18 | 0.080 |
Why?
| | Administration, Oral | 1 | 2008 | 58 | 0.080 |
Why?
| | Attitude to Health | 1 | 2008 | 26 | 0.080 |
Why?
| | Prevalence | 1 | 2008 | 146 | 0.080 |
Why?
| | Adolescent Behavior | 1 | 2008 | 43 | 0.080 |
Why?
| | Age Factors | 1 | 2008 | 210 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 108 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2024 | 22 | 0.060 |
Why?
| | Omalizumab | 1 | 2023 | 1 | 0.060 |
Why?
| | Immunotherapy | 1 | 2023 | 16 | 0.060 |
Why?
| | Chronic Disease | 1 | 2022 | 105 | 0.050 |
Why?
| | Genomics | 1 | 2023 | 101 | 0.050 |
Why?
| | Medicaid | 1 | 2022 | 38 | 0.050 |
Why?
| | Research | 1 | 2021 | 13 | 0.050 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 17 | 0.050 |
Why?
| | Breast Feeding | 1 | 2021 | 25 | 0.050 |
Why?
| | Registries | 1 | 2021 | 92 | 0.050 |
Why?
| | Pregnancy | 1 | 2021 | 216 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2016 | 13 | 0.030 |
Why?
| | Algorithms | 1 | 2016 | 105 | 0.030 |
Why?
| | Egg Hypersensitivity | 1 | 2013 | 2 | 0.030 |
Why?
| | Soy Foods | 1 | 2013 | 2 | 0.030 |
Why?
| | Milk Hypersensitivity | 1 | 2013 | 3 | 0.030 |
Why?
| | Ovum | 1 | 2013 | 3 | 0.030 |
Why?
| | Milk | 1 | 2013 | 6 | 0.030 |
Why?
| | Peanut Hypersensitivity | 1 | 2013 | 7 | 0.030 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2013 | 3 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 7 | 0.030 |
Why?
| | Allergens | 1 | 2013 | 58 | 0.030 |
Why?
| | Syndrome | 1 | 2012 | 34 | 0.030 |
Why?
| | Folic Acid | 1 | 2011 | 17 | 0.030 |
Why?
| | Reference Values | 1 | 2011 | 39 | 0.020 |
Why?
| | Methotrexate | 1 | 2011 | 30 | 0.020 |
Why?
| | Arthritis, Juvenile | 1 | 2011 | 31 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 1991 | 2 | 0.020 |
Why?
| | Random Allocation | 1 | 1991 | 7 | 0.020 |
Why?
| | Remission Induction | 1 | 1991 | 24 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1991 | 46 | 0.020 |
Why?
| | Recurrence | 1 | 1991 | 110 | 0.020 |
Why?
| | Incidence | 1 | 1991 | 133 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|